{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:03:25Z","timestamp":1789995805846,"version":"4.0.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014805","name":"Roche Italia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014805","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s41669-026-00672-9","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:44:39Z","timestamp":1785761079000},"page":"847-857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Subcutaneous Ocrelizumab for the Treatment of Relapsing Forms of Multiple Sclerosis: A Budget Impact Model"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8402-6934","authenticated-orcid":false,"given":"Camilla","family":"Porta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Di Procolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Marrazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Belfiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Palladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Brescia Morra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Moccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"672_CR1","unstructured":"MSIF - Multiple Sclerosis International Federation. Atlas of MS [Internet]. 2020 [cited 2024 Feb 13]. https:\/\/www.atlasofms.org\/map\/united-kingdom\/epidemiology\/number-of-people-with-ms. Accessed 13 Feb 2024."},{"key":"672_CR2","unstructured":"Associazione Italiana Sclerosi Multipla APS\/ETS. BAROMETRO della SCLEROSI MULTIPLA e patologie correlate. [Internet]. 2025 [cited 2025 Nov 4]. https:\/\/agenda.aism.it\/2024\/download\/Barometro_della_Sclerosi_Multipla_2025.pdf. Accessed 4 Nov 2025."},{"key":"672_CR3","doi-asserted-by":"publisher","unstructured":"Eandi M. Pharmacoeconomic aspects of poor adherence to treatment in multiple sclerosis management. Farmeconomia Health economics and therapeutic pathways; Vol 12, No 3 (2011) [Internet]. 2011; https:\/\/doi.org\/10.7175\/fe.v12i3.127.","DOI":"10.7175\/fe.v12i3.127"},{"key":"672_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.36469\/jheor.2022.33288","volume":"9","author":"G Pardo","year":"2022","unstructured":"Pardo G, Pineda ED, Ng CD, Sheinson D, Bonine NG. The association between persistence and adherence to disease-modifying therapies and healthcare resource utilization and costs in patients with multiple sclerosis. J Health Econ Outcomes Res. 2022;9:111\u20136. https:\/\/doi.org\/10.36469\/jheor.2022.33288.","journal-title":"J Health Econ Outcomes Res"},{"key":"672_CR5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/13524585221074010","volume":"28","author":"M Moccia","year":"2022","unstructured":"Moccia M, Affinito G, Ronga B, Giordana R, Fumo MG, Lanzillo R, et al. Emergency medical care for multiple sclerosis: a five-year population study in the Campania Region (South Italy). Mult Scler. 2022;28:597\u2013607. https:\/\/doi.org\/10.1177\/13524585221074010.","journal-title":"Mult Scler"},{"key":"672_CR6","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383:546\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1917246.","journal-title":"N Engl J Med"},{"key":"672_CR7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205584","volume":"102","author":"S Hauser","year":"2024","unstructured":"Hauser S, Kappos L, Filippi M, Wolinsky J, Weber M, Nicholas J, et al. 10 years of ocrelizumab treatment in multiple sclerosis: long-term efficacy and safety clinical trial data (S31.005). Neurology. 2024;102:5124. https:\/\/doi.org\/10.1212\/WNL.0000000000205584.","journal-title":"Neurology"},{"key":"672_CR8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/neurolint16020029","volume":"16","author":"M Moccia","year":"2024","unstructured":"Moccia M, Affinito G, Marrazzo G, Ciarambino T, Di Procolo P, Confalonieri L, et al. Utilization of ocrelizumab within different treatment strategies for multiple sclerosis: a 5-year population-based study. Neurol Int. 2024;16:394\u2013405. https:\/\/doi.org\/10.3390\/neurolint16020029.","journal-title":"Neurol Int"},{"key":"672_CR9","unstructured":"Pineda ED, Miller A, Patel A, Pardo G. Real-world adherence and persistence to ocrelizumab vs of atumumab among people with multiple sclerosis over 24 months. ACTRIMS Forum. 2025."},{"key":"672_CR10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205244","volume":"102","author":"S Newsome","year":"2024","unstructured":"Newsome S, Krzystanek E, Selmaj K, Goldstick L, Figueiredo C, Townsend B, et al. OCARINA II, phase III study: results of subcutaneous ocrelizumab administration in patients with multiple sclerosis (S31.006). Neurology. 2024;102:3597. https:\/\/doi.org\/10.1212\/WNL.0000000000205244.","journal-title":"Neurology"},{"key":"672_CR11","doi-asserted-by":"publisher","unstructured":"Cortesi PA, Paolicelli D, Capobianco M, Cozzolino P, Mantovani LG. The value and sustainability of ocrelizumab in relapsing multiple sclerosis: a cost-effectiveness and budget impact analysis. Farmeconomia Health Econ Ther Pathw. 2019;20(1) [Internet]. https:\/\/doi.org\/10.7175\/fe.v20i1.1435.","DOI":"10.7175\/fe.v20i1.1435"},{"key":"672_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s41669-022-00381-z","volume":"7","author":"P Martins","year":"2023","unstructured":"Martins P, Vandewalle B, F\u00e9lix J, Capela CM, Cerqueira JJ, Salgado AV, et al. Cost-effectiveness analysis of ocrelizumab for the treatment of relapsing and primary progressive multiple sclerosis in Portugal. Pharmacoecon Open. 2023;7:229\u201341. https:\/\/doi.org\/10.1007\/s41669-022-00381-z.","journal-title":"Pharmacoecon Open"},{"key":"672_CR13","unstructured":"AIFA. DET PRES\/HTA 826\/2025 Aggiornamento scheda prescrizione cartacea per la prescrizione dei farmaci disease modifying per la Sclerosi Multipla per linee di trattamento successive alla prima o per forme G [Internet]. 2025 [cited 2025 Nov 11]. https:\/\/trovanorme.aifa.gov.it\/#\/ricerca-rapida\/dettaglioAIFA\/05382257-503e-4081-a16a-6f580f8be14b?dataPubblicazione=2025-06-12T00:00:00Z. Accessed 11 Nov 2025"},{"key":"672_CR14","unstructured":"ISTAT. Popolazione residente 01-01-2025. [Internet]. [cited 2024 Apr 1]. https:\/\/demo.istat.it\/app\/?i=POS. Accessed 1 Apr 2024."},{"key":"672_CR15","unstructured":"Stethos Market research. 2025. Data on file."},{"key":"672_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1601277.","journal-title":"N Engl J Med"},{"key":"672_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004073","volume":"4","author":"J Palace","year":"2014","unstructured":"Palace J, Bregenzer T, Tremlett H, Oger J, Zhu F, Boggild M, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open. 2014;4:e004073. https:\/\/doi.org\/10.1136\/bmjopen-2013-004073.","journal-title":"BMJ Open"},{"key":"672_CR18","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3111\/13696998.2015.1135805","volume":"19","author":"J Mauskopf","year":"2016","unstructured":"Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. J Med Econ. 2016;19:432\u201342. https:\/\/doi.org\/10.3111\/13696998.2015.1135805.","journal-title":"J Med Econ"},{"key":"672_CR19","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0016","volume":"12","author":"IA Samjoo","year":"2023","unstructured":"Samjoo IA, Drudge C, Walsh S, Tiwari S, Brennan R, Boer I, et al. Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis. J Comp Effect Res. 2023;12:e230016. https:\/\/doi.org\/10.57264\/cer-2023-0016.","journal-title":"J Comp Effect Res."},{"key":"672_CR20","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3111\/13696998.2013.774281","volume":"16","author":"DW Brandes","year":"2013","unstructured":"Brandes DW, Raimundo K, Agashivala N, Kim E. Implications of real-world adherence on cost-effectiveness analysis in multiple sclerosis. J Med Econ. 2013;16:547\u201351. https:\/\/doi.org\/10.3111\/13696998.2013.774281.","journal-title":"J Med Econ"},{"key":"672_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104866","volume":"77","author":"L Amezcua","year":"2023","unstructured":"Amezcua L, Livingston T, Hayward B, Zhou J, Williams MJ. Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: a claims analysis of real-world data. Mult Scler Relat Disord. 2023;77:104866. https:\/\/doi.org\/10.1016\/j.msard.2023.104866.","journal-title":"Mult Scler Relat Disord"},{"key":"672_CR22","unstructured":"ISTAT. Tavole di mortalit\u00e0 [Internet]. 2024 [cited 2025 Mar 19]. http:\/\/dati.istat.it\/Index.aspx?DataSetCode=DCIS_MORTALITA1. Accessed 19 Mar 2025."},{"key":"672_CR23","first-page":"101","volume":"29","author":"RJ Pokorski","year":"1997","unstructured":"Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med. 1997;29:101\u20136.","journal-title":"J Insur Med"},{"key":"672_CR24","unstructured":"NICE. Ponesimod for treating relapsing multiple sclerosis. TA767. [Internet]. 2022 [cited 2025 Mar 25]. https:\/\/www.nice.org.uk\/guidance\/ta767\/evidence\/appraisal-consultation-committee-papers-pdf-10951339933. Accessed 25 Mar 2025."},{"key":"672_CR25","unstructured":"NICE. Ocrelizumab for treating relapsing\u2013remitting multiple sclerosis. TA533. [Internet]. 2018 [cited 2024 Feb 16]. https:\/\/www.nice.org.uk\/guidance\/ta533. Accessed 16 Feb 2024."},{"key":"672_CR26","unstructured":"Eurostat. Harmonised indices of consumer prices (HICP). [Internet]. [cited 2024 Feb 16]. https:\/\/ec.europa.eu\/eurostat\/web\/main\/data\/database. Accessed 16 Feb 2024."},{"key":"672_CR27","doi-asserted-by":"publisher","unstructured":"Filippi M, Grimaldi L, Brescia Morra V, Conte A, Cordioli C, Totaro R, et al. Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study. ECTRIMS 2025 Late Breaking Poster P930, vol. 31. Mult Scler. SAGE Publications Ltd STM; 2025. p. 1342\u201390. https:\/\/doi.org\/10.1177\/13524585251370543.","DOI":"10.1177\/13524585251370543"},{"key":"672_CR28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s00415-023-11955-0","volume":"271","author":"M Filippi","year":"2024","unstructured":"Filippi M, Grimaldi L, Conte A, Totaro R, Valente MR, Malucchi S, et al. Intravenous or subcutaneous natalizumab in patients with relapsing\u2013remitting multiple sclerosis: investigation on efficiency and savings\u2014the EASIER study. J Neurol. 2024;271:340\u201354. https:\/\/doi.org\/10.1007\/s00415-023-11955-0.","journal-title":"J Neurol"},{"key":"672_CR29","unstructured":"AIFA. Ponvory. Compressa rivestita con film. Riassunto delle Caratteristiche del Prodotto."},{"key":"672_CR30","unstructured":"AIFA. Tysabri. Concentrato per soluzione per infusione. Riassunto delle Caratteristiche del Prodotto."},{"key":"672_CR31","unstructured":"AIFA. Tysabri. Soluzione iniettabile. Riassunto delle Caratteristiche del Prodotto."},{"key":"672_CR32","unstructured":"AIFA. Zeposia. Capsula rigida. Riassunto delle Caratteristiche del Prodotto."},{"key":"672_CR33","unstructured":"AIFA. Ocrevus. Concentrato per soluzione per infusione. Riassunto delle Caratteristiche del Prodotto."},{"key":"672_CR34","unstructured":"AIFA. Mavenclad. Compressa. Riassunto delle Caratteristiche del Prodotto."},{"key":"672_CR35","unstructured":"AIFA. Lemtrada. Concentrato per soluzione iniettabile. Riassunto delle Caratteristiche del Prodotto."},{"key":"672_CR36","unstructured":"AIFA. Kesimpta. Soluzione iniettabile. Riassunto delle Caratteristiche del Prodotto."},{"key":"672_CR37","unstructured":"AIFA. Gilenya. Capsula rigida. Riassunto delle Caratteristiche del Prodotto."},{"key":"672_CR38","unstructured":"AIFA. Briumvi. Concentrato per soluzione per infusione. Riassunto delle Caratteristiche del Prodotto."},{"key":"672_CR39","doi-asserted-by":"publisher","unstructured":"Stanisic S, Bertolotto A, Berto P, Procolo PD, Morawski J. The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy. Glob Reg Health Technol Assess [Internet]. 2019 [cited 2024 Feb 16];6. https:\/\/doi.org\/10.33393\/grhta.2019.465.","DOI":"10.33393\/grhta.2019.465"},{"key":"672_CR40","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s41669-022-00363-1","volume":"6","author":"M Baharnoori","year":"2022","unstructured":"Baharnoori M, Bhan V, Clift F, Thomas K, Mouallif S, Adlard N, et al. Cost-effectiveness analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada. PharmacoEconomics Open. 2022;6:859\u201370. https:\/\/doi.org\/10.1007\/s41669-022-00363-1.","journal-title":"PharmacoEconomics Open"},{"key":"672_CR41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.19156\/abtpn.2015.0008","volume":"1","author":"L Moiola","year":"2015","unstructured":"Moiola L. Il monitoraggio della terapia nel paziente con sclerosi multipla. AboutOpen. 2015;1:46\u201356. https:\/\/doi.org\/10.19156\/abtpn.2015.0008.","journal-title":"AboutOpen"},{"key":"672_CR42","unstructured":"Cacciaguerra L. Cladribina: dati dalle prime esperienze cliniche nei Centri italiani. 2020."},{"key":"672_CR43","unstructured":"AISM. Associazione Italiana Sclerosi Multipla. [Internet]. [cited 2025 Mar 25]. https:\/\/www.aism.it\/. Accessed 25 Mar 2025."},{"key":"672_CR44","unstructured":"Ministero della Salute. Definizione delle tariffe dell\u2019assistenza specialistica ambulatoriale e protesica. Decreto 06\/2023 pubblicato in GU Serie Generale n.181 del 04-08-2013."},{"key":"672_CR45","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","volume":"387","author":"L Steinman","year":"2022","unstructured":"Steinman L, Fox E, Hartung H-P, Alvarez E, Qian P, Wray S, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387:704\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2201904.","journal-title":"N Engl J Med"},{"key":"672_CR46","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","volume":"18","author":"G Comi","year":"2019","unstructured":"Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18:1009\u201320. https:\/\/doi.org\/10.1016\/S1474-4422(19)30239-X.","journal-title":"Lancet Neurol"},{"key":"672_CR47","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(12)61769-3.","journal-title":"Lancet"},{"key":"672_CR48","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","volume":"18","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019;18:1021\u201333. https:\/\/doi.org\/10.1016\/S1474-4422(19)30238-8.","journal-title":"Lancet Neurol"},{"key":"672_CR49","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(12)61768-1.","journal-title":"Lancet"},{"key":"672_CR50","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","volume":"78","author":"L Kappos","year":"2021","unstructured":"Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdov\u00e1 EK, Hennessy B, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial. JAMA Neurol. 2021;78:558\u201367. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0405.","journal-title":"JAMA Neurol"},{"key":"672_CR51","unstructured":"Ministero dell\u2019Economia e delle Finanze. Libro verde sulla spesa pubblica [Internet]. 2007 [cited 2025 Nov 4]. https:\/\/www.mef.gov.it\/export\/sites\/MEF\/ministero\/commissioni\/ctfp\/documenti\/Libro_verde_spesa_pubblica.pdf. Accessed 4 Nov 2025."},{"key":"672_CR52","unstructured":"Ministero della Salute. Rapporto annuale sull\u2019attivit\u00e0 di ricovero ospedaliero\u2014DATI SDO 2022 [Internet]. 2024 [cited 2025 Nov 4]. https:\/\/www.salute.gov.it\/portale\/documentazione\/p6_2_2_1.jsp?lingua=italiano&id=3441. Accessed 4 Nov 2025."},{"key":"672_CR53","doi-asserted-by":"publisher","first-page":"A721","DOI":"10.1016\/j.jval.2017.08.1934","volume":"20","author":"P Cozzolino","year":"2017","unstructured":"Cozzolino P, Cortesi PA, Cesana G, Capra R, Mantovani LG. The economic burden of different multiple sclerosis phenotypes. Value Health. 2017;20:A721. https:\/\/doi.org\/10.1016\/j.jval.2017.08.1934.","journal-title":"Value Health"},{"key":"672_CR54","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1352458517708176","volume":"23","author":"M Battaglia","year":"2017","unstructured":"Battaglia M, Kobelt G, Ponzio M, Berg J, Capsa D, Dal\u00e9n J. New insights into the burden and costs of multiple sclerosis in Europe: results for Italy. Mult Scler. 2017;23:104\u201316. https:\/\/doi.org\/10.1177\/1352458517708176.","journal-title":"Mult Scler"},{"key":"672_CR55","doi-asserted-by":"publisher","unstructured":"Mantovani LG, Cortesi PA, Cardillo A, Santoni L, Prosperini L. Cost-effectiveness of dimethyl fumarate compared to teriflunomide for relapsing remitting multiple sclerosis patients in Italy. FE [Internet]. 2022 [cited 2024 Mar 25];23. https:\/\/doi.org\/10.7175\/fe.v23i1.1510.","DOI":"10.7175\/fe.v23i1.1510"},{"key":"672_CR56","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13173-2","volume":"272","author":"C Gasperini","year":"2025","unstructured":"Gasperini C, Centonze D, Conte A, Gallo P, Lugaresi A, Patti F, et al. Personalized therapy in multiple sclerosis: an Italian Delphi consensus. J Neurol. 2025;272:428. https:\/\/doi.org\/10.1007\/s00415-025-13173-2.","journal-title":"J Neurol"},{"key":"672_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12725-2","volume":"272","author":"C Gasperini","year":"2024","unstructured":"Gasperini C, Battaglia MA, Balzani F, Chiarini E, Pani M, Pasqualetti P, et al. Unveiling preferences in multiple sclerosis care: insights from an Italian discrete-choice experiment with patients and healthcare professionals. J Neurol. 2024;272:27. https:\/\/doi.org\/10.1007\/s00415-024-12725-2.","journal-title":"J Neurol"},{"key":"672_CR58","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00228-024-03783-6","volume":"81","author":"M Jafari","year":"2025","unstructured":"Jafari M, Sebty M, Moradi S, Noqani H, Esmaily H, Mohammadnezhad G. Identification of the most cost-saving disease-modifying therapies and factors affecting the budget in the pharmacotherapy of multiple sclerosis: a systematic review. Eur J Clin Pharmacol. 2025;81:247\u201367. https:\/\/doi.org\/10.1007\/s00228-024-03783-6.","journal-title":"Eur J Clin Pharmacol"},{"key":"672_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-025-04338-7","volume":"25","author":"M K\u00f6hler","year":"2025","unstructured":"K\u00f6hler M, Paul F, Janke K, Sturtz S, Preukschat D, Ostlender S, et al. Comparative effectiveness of disease-modifying therapies for highly active relapsing-remitting multiple sclerosis despite previous treatment\u2014a systematic review and network meta-analysis. BMC Neurol. 2025;25:328. https:\/\/doi.org\/10.1186\/s12883-025-04338-7.","journal-title":"BMC Neurol"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00672-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-026-00672-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00672-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:13:34Z","timestamp":1789992814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-026-00672-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["672"],"URL":"https:\/\/doi.org\/10.1007\/s41669-026-00672-9","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CP is an employee of AdRes, which has received funding from Roche for the conduct of the study. PDP, GM, and MB are employees of Roche S.p.A. In the last 3 years, RP has received support from the UK MS Society and has taken part in advisory boards\/consultancy for MSD and Sanofi. VBM received research grants from the Italian MS Society and Roche, and honoraria from Bayer, Biogen, BMS Celgene, Merck, Mylan, Novartis, Roche, Sanofi-Genzyme, and Teva. MM has nothing to disclose other than what is declared in the funding statement.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study are available from the corresponding author, CP, upon reasonable request.","order":2,"name":"Ethics","label":"Data availability statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a budget impact model. No ethical approval is required.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The model that supports the findings of this study is available from the corresponding author, CP, upon reasonable request.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: Camilla Porta, Paolo Di Procolo, Marco Belfiore; Methodology: Camilla Porta, Paolo Di Procolo, Giuseppina Marrazzo, Marco Belfiore; Formal analysis and investigation: Camilla Porta; Writing\u2014original draft preparation: Camilla Porta; Writing\u2014review and editing: Paolo Di Procolo, Giuseppina Marrazzo, Marco Belfiore, Raffaele Palladino, Vincenzo Brescia Morra, Marcello Moccia; Funding acquisition: Paolo Di Procolo, Marco Belfiore; Project administration: Paolo Di Procolo, Marco Belfiore; Validation: Giuseppina Marrazzo, Raffaele Palladino, Vincenzo Brescia Morra, Marcello Moccia; Supervision: Paolo Di Procolo, Giuseppina Marrazzo, Marco Belfiore, Raffaele Palladino, Vincenzo Brescia Morra, Marcello Moccia. All authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}